Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Shares Outstanding (2022 - 2025)

Historic Shares Outstanding for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $4.1 million.

  • 60 Degrees Pharmaceuticals' Shares Outstanding rose 100217.56% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 100217.56%. This contributed to the annual value of $566908.0 for FY2024, which is 48536.45% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Shares Outstanding stood at $4.1 million for Q3 2025, which was up 100217.56% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Shares Outstanding ranged from a high of $4.1 million in Q3 2025 and a low of $39768.0 during Q4 2022
  • In the last 4 years, 60 Degrees Pharmaceuticals' Shares Outstanding had a median value of $427852.0 in 2023 and averaged $1.0 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first crashed by 9169.45% in 2023, then surged by 100217.56% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Shares Outstanding (Quarter) stood at $39768.0 in 2022, then soared by 143.53% to $96847.0 in 2023, then surged by 485.36% to $566908.0 in 2024, then soared by 624.01% to $4.1 million in 2025.
  • Its Shares Outstanding stands at $4.1 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.5 million for Q1 2025.